Patient characteristics
| UPI . | Sex/age, y . | Disease stage . | Prior treatment . | Disease duration, mo . | HLA-Cw group . | Total donor KIR genes, n . | Inhibitory donor KIR genes, n . | Patient-donor KIR ligand mismatch . | Experiment performed* . |
|---|---|---|---|---|---|---|---|---|---|
| 365 | M/32 | CP | HU | 5 | 1,2 | 13 | 7 | No | 1,3 |
| 360 | M/34 | AP | HU, IFN, IM | 35 | 1,2 | 14 | 8 | No | 1,3 |
| 17 | M/18 | BC | BU, HU | 42 | 1,2 | 10 | 5 | Yes | 1,2 |
| 41 | M/46 | CP | HU | 18 | 1 | 16 | 8 | Yes | 1,3 |
| 28 | M/50 | CP | HU, IFN | 19 | 1,2 | 13 | 7 | No | 1,2 |
| FORKB | F/50 | CP | None | Diagnosis | NA | NA | NA | NA | 1,2 |
| 1 | M/47 | CP | HU | 6 | 1,2 | 13 | 7 | No | 1,2,3 |
| 400 | F/41 | AP | BU, HU, IFN, IM | 87 | 1 | 12 | 7 | Yes | 1,3 |
| 319 | M/25 | CP | HU | 4 | NA | NA | NA | NA | 1,2 |
| 10 | M/31 | CP | HU | 28 | 1,2 | 14 | 7 | Yes | 2,3 |
| 344 | F/46 | AP | HU, IM | 13 | 1 | 10 | 6 | Yes | 3 |
| 452 | M/44 | AP | IM | 44 | 1 | 11 | 6 | Yes | 3 |
| 481 | F/44 | BC | IM | 26 | 1 | 17 | 9 | Yes | 3 |
| 53 | M/46 | CP | HU | 10 | 2 | 9 | 6 | Yes | 2,3 |
| UPI . | Sex/age, y . | Disease stage . | Prior treatment . | Disease duration, mo . | HLA-Cw group . | Total donor KIR genes, n . | Inhibitory donor KIR genes, n . | Patient-donor KIR ligand mismatch . | Experiment performed* . |
|---|---|---|---|---|---|---|---|---|---|
| 365 | M/32 | CP | HU | 5 | 1,2 | 13 | 7 | No | 1,3 |
| 360 | M/34 | AP | HU, IFN, IM | 35 | 1,2 | 14 | 8 | No | 1,3 |
| 17 | M/18 | BC | BU, HU | 42 | 1,2 | 10 | 5 | Yes | 1,2 |
| 41 | M/46 | CP | HU | 18 | 1 | 16 | 8 | Yes | 1,3 |
| 28 | M/50 | CP | HU, IFN | 19 | 1,2 | 13 | 7 | No | 1,2 |
| FORKB | F/50 | CP | None | Diagnosis | NA | NA | NA | NA | 1,2 |
| 1 | M/47 | CP | HU | 6 | 1,2 | 13 | 7 | No | 1,2,3 |
| 400 | F/41 | AP | BU, HU, IFN, IM | 87 | 1 | 12 | 7 | Yes | 1,3 |
| 319 | M/25 | CP | HU | 4 | NA | NA | NA | NA | 1,2 |
| 10 | M/31 | CP | HU | 28 | 1,2 | 14 | 7 | Yes | 2,3 |
| 344 | F/46 | AP | HU, IM | 13 | 1 | 10 | 6 | Yes | 3 |
| 452 | M/44 | AP | IM | 44 | 1 | 11 | 6 | Yes | 3 |
| 481 | F/44 | BC | IM | 26 | 1 | 17 | 9 | Yes | 3 |
| 53 | M/46 | CP | HU | 10 | 2 | 9 | 6 | Yes | 2,3 |
UPI indicates unique patient identifier; M, male; CP, chronic phase; HU, hydroxyurea; AP, accelerated phase; IFN, interferon-α; IM, imatinib; BC, blast crisis; BU, busulphan; F, female; and NA, not applicable.
1 indicates quantitative real-time reverse-transcriptase PCR; 2, fluorescence in situ hybridization; and 3, cytotoxicity assay.